Medical Professionals

our clinical trials

bluebird bio is conducting clinical studies of investigational gene therapies in four diseases: transfusion-dependent β-thalassemia, severe sickle cell disease, cerebral adrenoleukodystrophy, and relapsed/refractory multiple myeloma.

For more information, follow the links below to the study listings on clinicaltrials.gov. Medical professionals may also email us at clinicaltrials@bluebirdbio.com for more information about study participation.

Cerebral Adrenoleukodystrophy (CALD)

Lenti-D

Phase 2/3 study

Starbeam ALD-102

Evaluating safety and efficacy of Lenti-D gene therapy in patients with CALD

STATUS: ACTIVE, NOT RECRUITING


Long-term follow-up

LTF-304

Monitoring long-term safety and efficacy of Lenti-D gene therapy in patients with CALD treated in bluebird-sponsored clinical trials

STATUS: ENROLLING BY INVITATION


Observational

ALD-103

Evaluating safety and efficacy of allogeneic hematopoietic stem cell transplantation in patients with CALD aged 17 or younger

STATUS: RECRUITING


Relapsed/Refractory Multiple Myeloma (MM)

bb2121 (in partnership with Celgene)

Phase 1 study

CRB-401

Dose-escalation and dose-expansion study of safety and efficacy of bb2121 CAR T therapy in relapsed/refractory MM

STATUS: ACTIVE, NOT RECRUITING


Long-term follow-up

LTF-305

Monitoring long-term safety and efficacy of bb2121 CAR T therapy in patients treated in bluebird-sponsored clinical trials

STATUS: ENROLLING BY INVITATION


bb21217

Phase 1 study

CRB-402

Dose-escalation and dose-expansion study of safety and efficacy of bb21217 CAR T therapy in relapsed/refractory MM

STATUS: RECRUITING


Long-term follow-up

LTF-306

Study initiation pending, enrollment by invitation

Severe Sickle Cell Disease (SCD)

LentiGlobin

Phase 1/2 Studies

HGB-206

Evaluating safety and efficacy of LentiGlobin gene therapy in patients with severe SCD

STATUS: RECRUITING

HGB-205

Evaluating safety and efficacy of LentiGlobin gene therapy in patients with TDT or severe SCD

STATUS: ACTIVE, NOT RECRUITING


Long-term follow-up

LTF-303

Monitoring long-term safety and efficacy of LentiGlobin gene therapy in patients with TDT or severe SCD treated in bluebird-sponsored clinical trials

STATUS: ENROLLING BY INVITATION


Transfusion-Dependent β-Thalassemia (TDT)

LentiGlobin

Phase 3 Studies

Northstar-2 HGB-207

Evaluating safety and efficacy of LentiGlobin gene therapy in patients with TDT and non-β00 genotypes

STATUS: RECRUITING

Northstar-3 HGB-212

Evaluating safety and efficacy of LentiGlobin gene therapy in patients with TDT and a β00 genotype


STATUS: RECRUITING


Phase 1/2 Studies

Northstar HGB-204

Evaluating safety and efficacy of LentiGlobin gene therapy in patients with TDT

STATUS: COMPLETED

HGB-205

Evaluating safety and efficacy of LentiGlobin gene therapy in patients with TDT or severe SCD

STATUS: ACTIVE, NOT RECRUITING


Long-term follow-up

LTF-303

Monitoring long-term safety and efficacy of LentiGlobin gene therapy in patients with TDT or severe SCD treated in bluebird-sponsored clinical trials

STATUS: ENROLLING BY INVITATION